History – Car T-Cell

Company History

Leverage agile frameworks to provide a robust synopsis for high level overviews. Iterative approaches to corporate strategy foster thinking.

Oncologist

1 Baseline clinical status assessment to determine patient’s eligibility.

2 Consent and compassionate use approval from hospital where necessary.

Hospital

3 Apheresis is conducted.

MGRC

4 Peripheral blood mononuclear cells (PBMC) isolation and CAR T-Cell manufacturing.

Oncologist

5 Pre-treatment conditioning, where necessary.

6 CAR T-Cell infusion.

7 Combination treatment (ICI, IL2, etc.), where necessary.

8 Post-treatment monitoring.

9 End of treatment. Efficacy assessment at months 3 and 6.

[bold_timeline_item_button title=”Expand” style=”” shape=”” color=”” size=”inline” url=”#” el_class=”bold_timeline_group_button”]

CONTACT USContact Us. It’s Easy.

CALL TODAY

+1 800 100 900

AUSTRALIA OFFICE

456 Ippsum Street, Melbourne, Vic

MONDAY - FRIDAY

9AM - 5PM

USA OFFICE

195 Devonshire St Boston, MA 02110

Results Driven Data

Book A Meeting

Results Driven Data

Book A Meeting

https://immunotherapy.life/wp-content/uploads/2020/05/image_illustrations_04.png

0123456789001234567890 %

Use the results every day to get real-time data about geographical distribution, product usage, or user behavior to boost ROI by 15-25%

0123456789001234567890 %

Bring to the table win-win survival strategies to ensure proactive domination. At the end of the day, going forward, a new normal

Open Positions

Our software development agency has a growth up to 30% per each year. If you are result-oriented, not afraid to take initiative – drop us a note and join our team!

Back-end developer

Front-end developer

Middle QA Engineer

TREATMENTS

SUPPORT

COMPANY

https://immunotherapy.life/wp-content/uploads/2021/02/MGRC-LogoFooter.png